StockNews.com assumed coverage on shares of Oragenics (NYSE:OGEN – Get Free Report) in a research note issued to investors on Friday. The firm set a “sell” rating on the stock.
Oragenics Price Performance
Shares of OGEN opened at $1.38 on Friday. The firm has a 50 day simple moving average of $1.28. Oragenics has a twelve month low of $1.00 and a twelve month high of $7.74. The stock has a market cap of $6.18 million, a price-to-earnings ratio of -0.15 and a beta of 0.40.
Oragenics (NYSE:OGEN – Get Free Report) last released its earnings results on Friday, March 29th. The company reported ($5.48) EPS for the quarter.
Oragenics Company Profile
Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.
See Also
- Five stocks we like better than Oragenics
- Why Special Dividends Can be a Delightful Surprise for Income Investors
- Roblox: The Bottom Just Fell Out of the Metaverse
- What is Insider Trading? What You Can Learn from Insider Trading
- Airbnb Stock Plummets After Earnings, But is It a Buy?
- Why Invest in High-Yield Dividend Stocks?
- Uber’s Earnings Drop Is Investors Opportunity
Receive News & Ratings for Oragenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oragenics and related companies with MarketBeat.com's FREE daily email newsletter.
